振东制药(300158.SZ)：中药1.1类新药星蒌承气颗粒IIa期临床试验首例受试者入组

Core Viewpoint - Zhendong Pharmaceutical (300158.SZ) has announced that its research and development of the traditional Chinese medicine Class 1 new drug, Xinglou Chengqi Granules, is currently undergoing Phase IIa clinical trials, with the first subject successfully enrolled for treatment recently [1] Group 1 - The drug is indicated for phlegm-dispelling and bowel-clearing, specifically for acute ischemic stroke with phlegm-heat obstructing the bowels, presenting symptoms such as hemiplegia, unilateral numbness, speech difficulties, dizziness, constipation, chest tightness with phlegm, abdominal pain and bloating, nausea, dry mouth with bitter taste, red tongue with yellow greasy coating, and slippery pulse [1]